Navigation Links
Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
Date:2/21/2012

SAN DIEGO, Feb. 21, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Citi 2012 Global Health Care Conference in New York.   

The live presentation takes place on Wednesday, February 29 at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600.  Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
2. Neurocrine Biosciences Reports Third Quarter 2011 Results
3. Neurocrine Biosciences Reports Second Quarter 2011 Results
4. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
5. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
6. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
7. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
8. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
9. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
10. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
11. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... NYElectronic devices with unprecedented efficiency and data ... that use built-in electric polarizations to read ... inside most popular data-driven technology. But ferroelectrics ... blocks, including a curious habit of "forgetting" ... the U.S. Department of Energy,s Brookhaven National ...
(Date:8/18/2014)... , August 18, 2014 ... Bioreactor Systems Market, By Application (Municipal Wastewater Treatment ... Flat Sheet and Multi Tubular), By Configuration (Internal/Submerged ... 2019", published by MarketsandMarkets, The market for membrane ... by 2019, growing at a CAGR of 15.28% ...
(Date:8/18/2014)... Toronto, Canada (PRWEB) August 18, 2014 ... land of opportunity for the clinical research industry. ... clinical trials due to its aging population; a ... in chronic diseases; a densely populated pool of ... enrolment. , Notwithstanding these positive points, China also ...
(Date:8/16/2014)... grant from the Walmart Foundation to build a robotic ... the manufacturing costs of goods, allowing those goods to ... built overseas. , The Walmart U.S. Manufacturing Innovation Grant ... awards to seven research and development institutions at the ... the collaboration between Walmart, the U.S. Conference of Mayors ...
Breaking Biology Technology:Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2UT Arlington receives Walmart, Walmart Foundation innovation grant 2UT Arlington receives Walmart, Walmart Foundation innovation grant 3
... , ... ... ... ...
... , ... ... ... ...
... ... ... ... ...
Cached Biology Technology:PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 2PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 3PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 4PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 5PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 6PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 7PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 8PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 9PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 10PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 11PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 12PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 13PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 14PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 15PDL BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Provides First Quarter 2010 Revenue Guidance 16AMA Honors NIH Chief Molecular Biologist Ira Pastan, M.D. With Top Government Service Award 2AMA Honors NIH Chief Molecular Biologist Ira Pastan, M.D. With Top Government Service Award 3YM sees nimotuzumab license unaffected by civil claim against licensor 2YM sees nimotuzumab license unaffected by civil claim against licensor 3YM sees nimotuzumab license unaffected by civil claim against licensor 4YM sees nimotuzumab license unaffected by civil claim against licensor 5
(Date:8/19/2014)... Some infants born with neonatal abstinence syndrome (NAS) ... difficult time going through withdrawal than others, but ... genetic and epigenetic (when genes are turned on ... potential factors, researchers at Boston University School of ... a first of its kind study to identify ...
(Date:8/19/2014)... in college biology and other science courses are ... ways, and now they have a new textbook ... Life Sciences," published this month by Princeton Press ... for Mathematical and Biological Synthesis (NIMBioS), teaches readers ... be used to explore and explain biological phenomena. ...
(Date:8/19/2014)... been awarded a nearly $40,000 grant from the National ... of the National Park Service (NPS) and U.S. Department ... study of the energy efficiency and cost effectiveness of ... climates. , Radiant barriers are reflective thermal insulations commonly ... thereby reducing the amount of heat emitted in the ...
Breaking Biology News(10 mins):In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2New textbook introduces undergraduates to mathematics for the life sciences 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... Va.Catheter Lysis of Thromboembolic Stroke (CLOTS)an intensive five-day ... Oct. 24-28 in Dallas, Texasprovides interventional radiologists, neurointerventionalists, ... opportunity to review, observe and discuss all aspects ... the third-leading cause of death in the United ...
... 2010 A yearlong beach study led by a ... at sub-tropical beaches face an increased risk of illness. ... beachgoers face when exposed to recreational marine water at ... contamination. B.E.A.C.H.E.S. (Beach Environmental Assessment and ...
... Calif. , July 28 DigitalPersona, ... protection solutions, today announced DigitalPersona® Pro Enterprise, a ... protection and communication security.  DigitalPersona Pro Enterprise helps ... mobile workforces -- full disk encryption (FDE), two-factor ...
Cached Biology News:Explore stroke care with Society of Interventional Radiology's CLOTS 2Study suggests swimmers at sub-tropical beaches show increased risk of illness 2DigitalPersona Delivers New Centrally-Managed Solution for Notebook Data Protection and Remote Access Security 2DigitalPersona Delivers New Centrally-Managed Solution for Notebook Data Protection and Remote Access Security 3DigitalPersona Delivers New Centrally-Managed Solution for Notebook Data Protection and Remote Access Security 4
... The DNA Engine Tetrad thermal cycler ... the pioneering PTC-200 DNA Engine cycler. ... the capacity with a footprint only ... throughput for laboratories that run massive ...
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... is for 2-D separations. The cell has a ... II xi multi-cell can be customized for several ... and cooling system. The PROTEAN II xi multi-cell ... XL multi-cell for a wider format that accommodates ...
Biology Products: